Search

Your search keyword '"Inzucchi, Silvio E."' showing total 2,130 results
Start Over Author "Inzucchi, Silvio E."
2,130 results on '"Inzucchi, Silvio E."'

253. U.S. PATTERNS OF DRUG UTILIZATION AND PRESCRIPTION FILLS FOR PROVEN CARDIOPROTECTIVE ANTI-HYPERGLYCEMIC AGENTS

Author

Nargesi, Arash Aghajani, primary, Clark, Callahan, additional, Liu, Mengni, additional, Chen, Lian, additional, Reddy, Abraham, additional, Amodeo, Samuel, additional, Oikonomou, Evangelos K., additional, Suchard, Marc, additional, Lipska, Kasia, additional, McGuire, Darren K., additional, Lin, Zhenqiu, additional, Inzucchi, Silvio E., additional, Krumholz, Harlan M., additional, and Khera, Rohan, additional

Published
2022
Full Text
View/download PDF

257. DAPAGLIFLOZIN IN PATIENTS WITH HEART FAILURE ACROSS A RANGE OF LEFT VENTRICULAR HYPERTROPHY IN THE DELIVER TRIAL

Author

Vaduganathan, Muthiah, Claggett, Brian, Kulac, Ian, Johansen, Niklas Dyrby, Reza, Nosheen, Jhund, Pardeep S., De Boer, Rudolf A., Hernandez, Adrian F., Inzucchi, Silvio E., Kosiborod, Mikhail, Lam, Carolyn S.P., Martinez, Felipe A., Shah, Sanjiv Jayendra, Desai, Akshay S., Petersson, Magnus, Langkilde, Anna Maria, McMurray, John J.V., and Solomon, Scott D.

Published
2024
Full Text
View/download PDF

258. METABOLIC EFFECTS OF DAPAGLIFLOZIN IN HEART FAILURE ACROSS THE SPECTRUM OF EJECTION FRACTION

Author

Selvaraj, Senthil, Patel, Shachi, Sauer, Andrew, McGarrah, Robert, Jones, Philip, Kwee, Lydia, Windsor, Sheryl L., Ilkayeva, Olga, Muehlbauer, Michael, Newgard, Christopher B., Borlaug, Barry, Kitzman, Dalane W., Shah, Sanjiv Jayendra, Margulies, Kenneth B., Husain, Mansoor, Inzucchi, Silvio E., McGuire, Darren K., Lanfear, David E., Javaheri, Ali, Umpierrez, Guillermo, Mentz, Robert John, Sharma, Kavita, Kosiborod, Mikhail, and Shah, Svati

Published
2024
Full Text
View/download PDF

259. THE EFFECT OF DAPAGLIFLOZIN ON DAYS OF FULL HEALTH LOST DUE TO DEATH, HOSPITALIZATION, AND IMPAIRED WELL-BEING IN DAPA-HF

Author

Kondo, Toru, Mogensen, Ulrik Madvig, Talebi, Atefeh, Gasparyan, Samvel, campbell, ross, Docherty, Kieran F., De Boer, Rudolf A., Inzucchi, Silvio E., K⊘ber, Lars, Kosiborod, Mikhail, Martinez, Felipe A., Sabatine, Marc Steven, Bengtsson, Olof, Sjoestrand, Mikaela, Vaduganathan, Muthiah, Solomon, Scott D., Jhund, Pardeep S., and McMurray, John J.V.

Published
2024
Full Text
View/download PDF

260. Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: findings from the EMPA‐REG OUTCOME ® trial

Author

Vaduganathan, Muthiah, Inzucchi, Silvio E., Sattar, Naveed, Fitchett, David H., Ofstad, Anne Pernille, Brueckmann, Martina, George, Jyothis T., Verma, Subodh, Mattheus, Michaela, Wanner, Christoph, Zinman, Bernard, and Butler, Javed

Abstract

Aims: \ud Insulin use in type 2 diabetes, while often necessary, is associated with hypoglycemia and weight gain, requires training, and may add significant costs. We evaluated the effects of empagliflozin versus placebo on subsequent insulin initiation or dosing changes in a large cardiovascular outcomes trial.\ud \ud Materials and Methods: \ud In EMPA-REG OUTCOME®, 7,020 patients with type 2 diabetes and cardiovascular disease received empagliflozin 10mg, 25mg, or placebo. Median follow-up was 3.1 years. After 12 weeks’ treatment, changes in background antihyperglycemic therapy were permitted. Among insulin-naïve patients, we assessed effects of pooled empagliflozin arms vs. placebo on time to initiation of insulin. Among insulin-treated patients, we assessed effects on time to increase or decrease in insulin dose >20%.\ud \ud Results: \ud In 3,633 (52%) participants not treated with insulin at baseline, empagliflozin reduced new use of insulin vs. placebo by 60% (7.1% vs. 16.4%; adjusted HR 0.40 [95% CI 0.32-0.49]; P20% insulin dose increase by 58% (14.4% vs. 29.3%; adjusted HR 0.42 [95% CI 0.36-0.49]; P20% insulin dose reductions without subsequent increases in HbA1c compared with placebo (9.2% vs. 4.9%; adjusted HR 1.87 [95% CI: 1.39-2.51]; P10% or >30% were considered.\ud \ud Conclusions: \ud In patients with type 2 diabetes and cardiovascular disease, empagliflozin markedly and durably delays insulin initiation and substantial increases in insulin dose while facilitating sustained reductions in insulin requirements over time.

Published
2021

261. Association of Dapagliflozin vs Placebo With Individual Kansas City Cardiomyopathy Questionnaire Components in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the DELIVER Trial

Author

Peikert, Alexander, Chandra, Alvin, Kosiborod, Mikhail N., Claggett, Brian L., Desai, Akshay S., Jhund, Pardeep S., Lam, Carolyn S. P., Inzucchi, Silvio E., Martinez, Felipe A., de Boer, Rudolf A., Hernandez, Adrian F., Shah, Sanjiv J., Janssens, Stefan P., Belohlávek, Jan, Borleffs, C. Jan Willem, Dobreanu, Dan, Langkilde, Anna Maria, Bengtsson, Olof, Petersson, Magnus, McMurray, John J. V., Solomon, Scott D., and Vaduganathan, Muthiah

Abstract

IMPORTANCE: Dapagliflozin has been shown to improve overall health status based on aggregate summary scores of the Kansas City Cardiomyopathy Questionnaire (KCCQ) in patients with heart failure (HF) with mildly reduced or preserved ejection fraction enrolled in the Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure (DELIVER) trial. A comprehensive understanding of the responsiveness of individual KCCQ items would allow clinicians to better inform patients on expected changes in daily living with treatment. OBJECTIVE: To examine the association of dapagliflozin treatment with changes in individual components of the KCCQ. DESIGN, SETTING, AND PARTICIPANTS: This is a post hoc exploratory analysis of DELIVER, a randomized double-blind placebo-controlled trial conducted at 353 centers in 20 countries from August 2018 to March 2022. KCCQ was administered at randomization and 1, 4, and 8 months. Scores of individual KCCQ components were scaled from 0 to 100. Eligibility criteria included symptomatic HF with left ventricular ejection fraction greater than 40%, elevated natriuretic peptide levels, and evidence of structural heart disease. Data were analyzed from November 2022 to February 2023. MAIN OUTCOMES AND MEASURES: Changes in the 23 individual KCCQ components at 8 months. INTERVENTIONS: Dapagliflozin, 10 mg, once daily or placebo. RESULTS: Baseline KCCQ data were available for 5795 of 6263 randomized patients (92.5%) (mean [SD] age, 71.5 [9.5] years; 3344 male [57.7%] and 2451 female [42.3%]). Dapagliflozin was associated with larger improvements in almost all KCCQ components at 8 months compared with placebo. The most significant improvements with dapagliflozin were observed in frequency of lower limb edema (difference, 3.2; 95% CI, 1.6-4.8; P < .001), sleep limitation by shortness of breath (difference, 3.0; 95% CI, 1.6-4.4; P < .001), and limitation in desired activities by shortness of breath (difference, 2.8; 95% CI, 1.3-4.3; P < .001). Similar treatment patterns were observed in longitudinal analyses integrating data from months 1, 4, and 8. Higher proportions of patients treated with dapagliflozin experienced improvements, and fewer had deteriorations across most individual components. CONCLUSIONS AND RELEVANCE: In this study of patients with HF with mildly reduced or preserved ejection fraction, dapagliflozin was associated with improvement in a broad range of individual KCCQ components, with the greatest benefits in domains related to symptom frequency and physical limitations. Potential improvements in specific symptoms and activities of daily living might be more readily recognizable and easily communicated to patients. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03619213

Published
2023
Full Text
View/download PDF

262. Effect of Dapagliflozin on Total Heart Failure Events in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Trial

Author

Jhund, Pardeep S., Claggett, Brian L., Talebi, Atefeh, Butt, Jawad H., Gasparyan, Samvel B., Wei, Lee-Jen, McCaw, Zachary R., Wilderäng, Ulrica, Bengtsson, Olof, Desai, Akshay S., Petersson, Magnus, Langkilde, Anna Maria, de Boer, Rudolf A., Hernandez, Adrian F., Inzucchi, Silvio E., Kosiborod, Mikhail N., Lam, Carolyn S. P., Martinez, Felipe A., Shah, Sanjiv J., Vaduganathan, Muthiah, Solomon, Scott D., and McMurray, John J. V.

Abstract

IMPORTANCE: In the Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure (DELIVER) trial, dapagliflozin reduced the risk of time to first worsening heart failure (HF) event or cardiovascular death in patients with HF with mildly reduced or preserved ejection fraction (EF). OBJECTIVE: To evaluate the effect of dapagliflozin on total (ie, first and recurrent) HF events and cardiovascular death in this population. DESIGN, SETTING, AND PARTICIPANTS: In this prespecified analysis of the DELIVER trial, the proportional rates approach of Lin, Wei, Yang, and Ying (LWYY) and a joint frailty model were used to examine the effect of dapagliflozin on total HF events and cardiovascular death. Several subgroups were examined to test for heterogeneity in the effect of dapagliflozin, including left ventricular EF. Participants were enrolled from August 2018 to December 2020, and data were analyzed from August to October 2022. INTERVENTIONS: Dapagliflozin, 10 mg, once daily or matching placebo. MAIN OUTCOMES AND MEASURES: The outcome was total episodes of worsening HF (hospitalization for HF or urgent HF visit requiring intravenous HF therapies) and cardiovascular death. RESULTS: Of 6263 included patients, 2747 (43.9%) were women, and the mean (SD) age was 71.7 (9.6) years. There were 1057 HF events and cardiovascular deaths in the placebo group compared with 815 in the dapagliflozin group. Patients with more HF events had features of more severe HF, such as higher N-terminal pro–B-type natriuretic peptide level, worse kidney function, more prior HF hospitalizations, and longer duration of HF, although EF was similar to those with no HF events. In the LWYY model, the rate ratio for total HF events and cardiovascular death for dapagliflozin compared with placebo was 0.77 (95% CI, 0.67-0.89; P < .001) compared with a hazard ratio of 0.82 (95% CI, 0.73-0.92; P < .001) in a traditional time to first event analysis. In the joint frailty model, the rate ratio was 0.72 (95% CI, 0.65-0.81; P < .001) for total HF events and 0.87 (95% CI, 0.72-1.05; P = .14) for cardiovascular death. The results were similar for total HF hospitalizations (without urgent HF visits) and cardiovascular death and in all subgroups, including those defined by EF. CONCLUSIONS AND RELEVANCE: In the DELIVER trial, dapagliflozin reduced the rate of total HF events (first and subsequent HF hospitalizations and urgent HF visits) and cardiovascular death regardless of patient characteristics, including EF. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03619213

Published
2023
Full Text
View/download PDF

263. Randomized Controlled Trial of the Hemodynamic Effects of Empagliflozin in Patients With Type 2 Diabetes at High Cardiovascular Risk: The SIMPLE Trial

Author

Wolsk, Emil, primary, Jürgens, Mikkel, additional, Schou, Morten, additional, Ersbøll, Mads, additional, Hasbak, Philip, additional, Kjær, Andreas, additional, Zerahn, Bo, additional, Brandt, Niels Høgh, additional, Gæde, Peter Haulund, additional, Rossing, Peter, additional, Faber, Jens, additional, Inzucchi, Silvio E., additional, Kistorp, Caroline Michaela, additional, and Gustafsson, Finn, additional

Published
2022
Full Text
View/download PDF

264. Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction

Author

Docherty, Kieran F., primary, Ogunniyi, Modele O., additional, Anand, Inder S., additional, Desai, Akshay S., additional, Diez, Mirta, additional, Howlett, Jonathan G., additional, Nicolau, Jose C., additional, O’Meara, Eileen, additional, Verma, Subodh, additional, Inzucchi, Silvio E., additional, Køber, Lars, additional, Kosiborod, Mikhail N., additional, Lindholm, Daniel, additional, Martinez, Felipe A., additional, Bengtsson, Olof, additional, Ponikowski, Piotr, additional, Sabatine, Marc S., additional, Sjöstrand, Mikaela, additional, Solomon, Scott D., additional, Langkilde, Anna Maria, additional, Jhund, Pardeep S., additional, and McMurray, John J.V., additional

Published
2022
Full Text
View/download PDF

266. Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials

Author

Rossing, Peter, primary, Inzucchi, Silvio E, additional, Vart, Priya, additional, Jongs, Niels, additional, Docherty, Kieran F, additional, Jhund, Pardeep S, additional, Køber, Lars, additional, Kosiborod, Mikhail N, additional, Martinez, Felipe A, additional, Ponikowski, Piotr, additional, Sabatine, Marc S, additional, Solomon, Scott D, additional, DeMets, David L, additional, Bengtsson, Olof, additional, Lindberg, Magnus, additional, Langkilde, Anna Maria, additional, Sjöstrand, Mikaela, additional, Stefansson, Bergur V, additional, Karlsson, Cecilia, additional, Chertow, Glenn M, additional, Hou, Fan Fan, additional, Correa-Rotter, Ricardo, additional, Toto, Robert D, additional, Wheeler, David C, additional, McMurray, John J V, additional, and Heerspink, Hiddo J L, additional

Published
2022
Full Text
View/download PDF

270. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial

Author

Butt, Jawad H., primary, Adamson, Carly, additional, Docherty, Kieran F., additional, de Boer, Rudolf A., additional, Petrie, Mark C., additional, Inzucchi, Silvio E., additional, Kosiborod, Mikhail N., additional, Maria Langkilde, Anna, additional, Lindholm, Daniel, additional, Martinez, Felipe A., additional, Bengtsson, Olof, additional, Schou, Morten, additional, O’Meara, Eileen, additional, Ponikowski, Piotr, additional, Sabatine, Marc S., additional, Sjöstrand, Mikaela, additional, Solomon, Scott D., additional, Jhund, Pardeep S., additional, McMurray, John J.V., additional, and Køber, Lars, additional

Published
2021
Full Text
View/download PDF

271. Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA‐HF

Author

Butt, Jawad H., primary, Docherty, Kieran F., additional, Jhund, Pardeep S., additional, de Boer, Rudolf A., additional, Böhm, Michael, additional, Desai, Akshay S., additional, Howlett, Jonathan G., additional, Inzucchi, Silvio E., additional, Kosiborod, Mikhail N., additional, Martinez, Felipe A., additional, Nicolau, Jose C., additional, Petrie, Mark C., additional, Ponikowski, Piotr, additional, Bengtsson, Olof, additional, Langkilde, Anna Maria, additional, Schou, Morten, additional, Sjöstrand, Mikaela, additional, Solomon, Scott D., additional, Sabatine, Marc S., additional, McMurray, John J.V., additional, and Køber, Lars, additional

Published
2021
Full Text
View/download PDF

273. Abstract 13846: Prognostic Value of Echocardiographic Markers of Diastolic Dysfunction for Heart Failure in Overweight and Obese Patients in CAMELLIA-TIMI 61

Author

Gong, Jingyi, primary, Scirica, Benjamin M, additional, Weissman, Neil J, additional, Tang, Minao, additional, Inzucchi, Silvio E, additional, McGuire, Darren K, additional, Keech, Anthony C, additional, Wiviott, Stephen D, additional, Sabatine, Marc S, additional, and Bohula, Erin, additional

Published
2021
Full Text
View/download PDF

275. Speaking to patients about diabetes risk: is terminology important?

Author

Tarasova, Valentina D., Caballero, Jaime A., Turner, Paul, and Inzucchi, Silvio E.

Subjects
Physician and patient, Prediabetic state, Endocrinology -- Terminology, Type 2 diabetes -- Risk factors, Patient education, Health
Abstract

It is estimated that 79 million people in the United States (35% of adults [greater than or equal to] 20 years of age and 50% of adults [greater than or [...]

Published
2014

277. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack

Author

Kernan, Walter N., Viscoli, Catherine M., Furie, Karen L., Young, Lawrence H., Inzucchi, Silvio E., Gorman, Mark, Guarino, Peter D., Lovejoy, Anne M., Peduzzi, Peter N., Conwit, Robin, Brass, Lawrence M., Schwartz, Gregory G., Adams, Harold P., Jr., Berger, Leo, Carolei, Antonio, Clark, Wayne, Coull, Bruce, Ford, Gary A., Kleindorfer, Dawn, OʼLeary, John R., Parsons, Mark W., Ringleb, Peter, Sen, Souvik, Spence, David J., Tanne, David, Wang, David, and Winder, Toni R.

Published
2016
Full Text
View/download PDF

280. Ketones: the double-edged sword of SGLT2 inhibitors?

Author

Lupsa, Beatrice C., Kibbey, Richard G., and Inzucchi, Silvio E.

Abstract

Sodium–glucose cotransporter 2 (SGLT2) inhibitors are a class of medications used by individuals with type 2 diabetes that reduce hyperglycaemia by targeting glucose transport in the kidney, preventing its reabsorption, thereby inducing glucosuria. Besides improving HbA1c and reducing body weight and blood pressure, the SGLT2 inhibitors have also been demonstrated to improve cardiovascular and kidney outcomes, an effect largely independent of their effect on blood glucose levels. Indeed, the mechanisms underlying these benefits remain elusive. Treatment with SGLT2 inhibitors has been found to modestly increase systemic ketone levels. Ketone bodies are an ancillary fuel source substituting for glucose in some tissues and may also possess intrinsic anti-oxidative and anti-inflammatory effects. Some have proposed that ketones may in fact mediate the cardio-renal benefits of this drug category. However, a rare complication of SGLT2 inhibition is ketoacidosis, sometimes with normal or near-normal blood glucose concentrations, albeit occurring more frequently in patients with type 1 diabetes who are treated (predominately off-label) with one of these agents. We herein explore the notion that an underpinning of one of the more serious adverse effects of SGLT2 inhibitors may, in fact, explain, at least in part, some of their benefits—a potential 'double-edged sword' of this novel drug category. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

284. Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF

Author

Docherty, Kieran F., Anand, Inder S., Chiang, Chern-En, Chopra, Vijay K., Desai, Akshay S., Kitakaze, Masafumi, Verma, Subodh, Vinh, Pham N., Inzucchi, Silvio E., Køber, Lars, Kosiborod, Mikhail N., Martinez, Felipe A., Bengtsson, Olof, Ponikowski, Piotr, Sabatine, Marc S., Sjöstrand, Mikaela, Solomon, Scott D., Langkilde, Anna Maria, Jhund, Pardeep S., and McMurray, John J.V.

Subjects
Asia, heart failure, SGLT2 inhibitor, ejection fraction
Abstract

Background: \ud Patients with heart failure with reduced ejection fraction (HFrEF) in Asia exhibit many differences from those in other parts of the world.\ud \ud Objectives: \ud This study sought to investigate the efficacy and safety of dapagliflozin, compared with placebo, in HFrEF patients in Asia, compared with those elsewhere, enrolled in the DAPA-HF (Dapagliflozin and Prevention of Adverse-outcomes in Heart Failure) trial.\ud \ud Methods: \ud Patients in New York Heart Association functional class II to IV with a left ventricular ejection fraction ≤40% and elevated N-terminal pro–B-type natriuretic peptide were eligible for the DAPA-HF trial. The primary outcome in the DAPA-HF trial was the composite of an episode of worsening HF (HF hospitalization or urgent HF visit requiring intravenous therapy) or cardiovascular death.\ud \ud Results: \ud Of the 4,744 patients in the DAPA-HF trial, 1,096 (23.1%) were enrolled in Asia; 721 (15.2% overall, 65.8% of patients in Asia) were enrolled in East Asia (237 in China, 343 in Japan, and 141 in Taiwan), 138 (2.9% overall, 12.6% in Asia) in South-East Asia (Vietnam), and 237 (5.0% overall, 21.6% in Asia) in South Asia (India). Patients from Asia had similar rates of worsening HF events and mortality compared with patients elsewhere. Compared with placebo, dapagliflozin reduced the risk of the primary endpoint to the same extent in patients from Asia (HR: 0.65; 95% CI: 0.49 to 0.87) as elsewhere (HR: 0.77; 95% CI: 0.66 to 0.89) (P for interaction = 0.32). Consistent benefits were observed for the other prespecified outcomes and among the regions of Asia. Study drug discontinuation and prespecified adverse events did not differ between regions.\ud \ud Conclusions: \ud Dapagliflozin, compared with placebo, reduced the risk of worsening HF events and cardiovascular death to the same extent in Asian patients as elsewhere. (Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure [DAPA-HF]; NCT03036124).

Published
2021

285. Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA-REG OUTCOME trial

Author

Pellicori, Pierpaolo, Fitchett, David, Kosiborod, Mihkail N., Ofstad, Anne P., Seman, Leo, Zinman, Bernard, Zwiener, Isabella, Wanner, Christoph, George, Jyothis, Inzucchi, Silvio E., Testani, Jeffrey M., and Cleland, John G.F.

Abstract

Background: \ud Loop diuretics (LD) relieve symptoms and signs of congestion due to heart failure (HF), but many patients prescribed LD do not have such a diagnosis.\ud \ud Aims and methods: \ud We studied the relationship between HF diagnosis, use of LD, and outcomes in four patient subgroups with type-2 diabetes mellitus (T2DM) in EMPA-REG OUTCOME; [i) investigator-reported HF on LD, ii) investigator-reported HF not on LD, iii] no HF on LD, and iv) no HF and not on LD], and assessed their risk of CV events.\ud \ud Results: \ud Of 7,020 participants, at baseline, 706 (10%) had a diagnosis of HF, of whom 334 were prescribed LD. However, 755 (11%) patients who did not have a diagnosis of HF were prescribed LD. Compared to those with neither HF nor prescribed LD (reference group; placebo), those with both HF and receiving LD had the highest rates for all-cause (hazard ratio [HR] [95% CI]: 3.19 [2.03-5.01]) and CV mortality (3.83 [2.28-6.44]), and HF hospitalisations (HHF) (9.51 [5.61-16.14]). Patients without HF but prescribed LD had higher rates for all three outcomes (1.62 [1.10-2.39]); 1.97 [1.26-3.08]); 3.20 [1.90-5.39]), which were similar to patients with HF who were not receiving LD (1.42 [0.78-2.57]; 1.56 [0.78-3.11]; 3.00 [1.40-6.40)]). Empagliflozin had similar benefits regardless of subgroup (p for interaction >0.1 for all outcomes).\ud \ud Conclusion: \ud Patients with T2DM prescribed LD are at greater risk of CV events even if they are not reported to have HF; this might reflect under-diagnosis. Empagliflozin was similarly effective in all subgroups investigated.

Published
2021

286. Effect of empagliflozin on myocardial structure and function in patients with type 2 diabetes at high cardiovascular risk: the SIMPLE randomized clinical trial

Author

Ersbøll, Mads, primary, Jürgens, Mikkel, additional, Hasbak, Philip, additional, Kjær, Andreas, additional, Wolsk, Emil, additional, Zerahn, Bo, additional, Brandt-Jacobsen, Niels H., additional, Gæde, Peter, additional, Rossing, Peter, additional, Faber, Jens, additional, Inzucchi, Silvio E., additional, Gustafsson, Finn, additional, Schou, Morten, additional, and Kistorp, Caroline, additional

Published
2021
Full Text
View/download PDF

287. Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA‐REG OUTCOME trial

Author

Vaduganathan, Muthiah, primary, Inzucchi, Silvio E., additional, Sattar, Naveed, additional, Fitchett, David H., additional, Ofstad, Anne Pernille, additional, Brueckmann, Martina, additional, George, Jyothis T., additional, Verma, Subodh, additional, Mattheus, Michaela, additional, Wanner, Christoph, additional, Zinman, Bernard, additional, and Butler, Javed, additional

Published
2021
Full Text
View/download PDF

288. Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA‐REG OUTCOME trial

Author

Fitchett, David, primary, Inzucchi, Silvio E., additional, Zinman, Bernard, additional, Wanner, Christoph, additional, Schumacher, Martin, additional, Schmoor, Claudia, additional, Ohneberg, Kristin, additional, Ofstad, Anne Pernille, additional, Salsali, Afshin, additional, George, Jyothis T., additional, Hantel, Stefan, additional, Bluhmki, Erich, additional, Lachin, John M., additional, and Zannad, Faiez, additional

Published
2021
Full Text
View/download PDF

290. Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF

Author

Curtain, James P, primary, Docherty, Kieran F, additional, Jhund, Pardeep S, additional, Petrie, Mark C, additional, Inzucchi, Silvio E, additional, Køber, Lars, additional, Kosiborod, Mikhail N, additional, Martinez, Felipe A, additional, Ponikowski, Piotr, additional, Sabatine, Marc S, additional, Bengtsson, Olof, additional, Langkilde, Anna Maria, additional, Sjöstrand, Mikaela, additional, Solomon, Scott D, additional, and McMurray, John J V, additional

Published
2021
Full Text
View/download PDF

291. Effects of Empagliflozin on Myocardial Flow Reserve in Patients With Type 2 Diabetes Mellitus: The SIMPLE Trial

Author

Jürgens, Mikkel, primary, Schou, Morten, additional, Hasbak, Philip, additional, Kjær, Andreas, additional, Wolsk, Emil, additional, Zerahn, Bo, additional, Wiberg, Mikkel, additional, Brandt‐Jacobsen, Niels H., additional, Gæde, Peter, additional, Rossing, Peter, additional, Faber, Jens, additional, Inzucchi, Silvio E., additional, Gustafsson, Finn, additional, and Kistorp, Caroline, additional

Published
2021
Full Text
View/download PDF

294. Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME Trial

Author

Savarese, Gianluigi, primary, Uijl, Alicia, additional, Lund, Lars H., additional, Anker, Stefan D., additional, Asselbergs, Folkert W., additional, Fitchett, David, additional, Inzucchi, Silvio E., additional, Koudstaal, Stefan, additional, Ofstad, Anne Pernille, additional, Schrage, Benedikt, additional, Vedin, Ola, additional, Wanner, Christoph, additional, Zannad, Faiez, additional, Zwiener, Isabella, additional, and Butler, Javed, additional

Published
2021
Full Text
View/download PDF

295. Patient Characteristics, Outcomes, and Effects of Dapagliflozin According to the Duration of Heart Failure: A Prespecified Analysis of the DELIVER Trial

Author

Kondo, Toru, Jering, Karola S., Borleffs, C. Jan Willem, de Boer, Rudolf A., Claggett, Brian L., Desai, Akshay S., Dobreanu, Dan, Inzucchi, Silvio E., Hernandez, Adrian F., Janssens, Stefan P., Jhund, Pardeep S., Kosiborod, Mikhail N., Lam, Carolyn S.P., Langkilde, Anna Maria, Martinez, Felipe A., Petersson, Magnus, Vinh, Pham Nguyen, Vaduganathan, Muthiah, Solomon, Scott D., and McMurray, John J.V.

Published
2023
Full Text
View/download PDF

296. Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum

Author

Butt, Jawad H., Docherty, Kieran F., Claggett, Brian L., Desai, Akshay S., Fang, James C., Petersson, Magnus, Langkilde, Anna Maria, de Boer, Rudolf A., Cabrera Honorio, Jose Walter, Hernandez, Adrian F., Inzucchi, Silvio E., Kosiborod, Mikhail N., Køber, Lars, Lam, Carolyn S.P., Martinez, Felipe A., Ponikowski, Piotr, Sabatine, Marc S., Vardeny, Orly, O'Meara, Eileen, Saraiva, Jose F.K., Shah, Sanjiv J., Vaduganathan, Muthiah, Jhund, Pardeep S., Solomon, Scott D., and McMurray, John J.V.

Abstract

Black people have a higher incidence and prevalence of heart failure (HF) than White people, and once HF has developed, they may have worse outcomes. There is also evidence that the response to several pharmacologic therapies may differ between Black and White patients.

Published
2023
Full Text
View/download PDF

297. Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid–Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout: A Patient-Level Pooled Meta-analysis of DAPA-HF and DELIVER

Author

Butt, Jawad H., Docherty, Kieran F., Claggett, Brian L., Desai, Akshay S., Petersson, Magnus, Langkilde, Anna Maria, de Boer, Rudolf A., Hernandez, Adrian F., Inzucchi, Silvio E., Kosiborod, Mikhail N., Køber, Lars, Lam, Carolyn S. P., Martinez, Felipe A., Ponikowski, Piotr, Sabatine, Marc S., Shah, Sanjiv J., Vaduganathan, Muthiah, Jhund, Pardeep S., Solomon, Scott D., and McMurray, John J. V.

Abstract

IMPORTANCE: Gout is common in patients with heart failure (HF), and sodium-glucose cotransporter 2 inhibitors, a foundational treatment for HF, reduce uric acid levels. OBJECTIVE: To examine the reported prevalence of gout at baseline, the association between gout and clinical outcomes, and the effect of dapagliflozin in patients with and without gout and the introduction of new uric acid–lowering therapy and colchicine. DESIGN, SETTING, AND PARTICIPANTS: This post hoc analysis used data from 2 phase 3 randomized clinical trials conducted in 26 countries, DAPA-HF (left ventricular ejection fraction [LVEF] ≤40%) and DELIVER (LVEF >40%). Patients with New York Heart Association functional class II through IV and elevated levels of N-terminal pro–B-type natriuretic peptide were eligible. Data were analyzed between September 2022 and December 2022. INTERVENTION: Addition of once-daily 10 mg of dapagliflozin or placebo to guideline-recommended therapy. MAIN OUTCOMES AND MEASURES: The primary outcome was the composite of worsening HF or cardiovascular death. RESULTS: Among 11 005 patients for whom gout history was available, 1117 patients (10.1%) had a history of gout. The prevalence of gout was 10.3% (488 of 4747 patients) and 10.1% (629 of 6258 patients) in those with an LVEF up to 40% and greater than 40%, respectively. Patients with gout were more often men (897 of 1117 [80.3%]) than those without (6252 of 9888 [63.2%]). The mean (SD) age was similar between groups, 69.6 (9.8) years for patients with gout and 69.3 (10.6) years for those without. Patients with a history of gout had a higher body mass index, more comorbidity, and lower estimated glomerular filtration rate and were more often treated with a loop diuretic. The primary outcome occurred at a rate of 14.7 per 100 person-years (95% CI, 13.0-16.5) in participants with gout compared with 10.5 per 100 person-years (95% CI, 10.1-11.0) in those without (adjusted hazard ratio [HR], 1.15; 95% CI, 1.01-1.31). A history of gout was also associated with a higher risk of the other outcomes examined. Compared with placebo, dapagliflozin reduced the risk of the primary end point to the same extent in patients with (HR, 0.84; 95% CI, 0.66-1.06) and without a history of gout (HR, 0.79; 95% CI, 0.71-0.87; P = .66 for interaction). The effect of dapagliflozin use with other outcomes was consistent in participants with and without gout. Initiation of uric acid–lowering therapy (HR, 0.43; 95% CI, 0.34-0.53) and colchicine (HR, 0.54; 95% CI, 0.37-0.80) was reduced by dapagliflozin compared with placebo. CONCLUSIONS AND RELEVANCE: This post hoc analysis of 2 trials found that gout was common in HF and associated with worse outcomes. The benefit of dapagliflozin was consistent in patients with and without gout. Dapagliflozin reduced the initiation of new treatments for hyperuricemia and gout. TRIAL REGISTRATION: ClinicalTrials.gov Identifiers: NCT03036124 and NCT03619213

Published
2023
Full Text
View/download PDF

298. Caring for Patients With Diabetes in Stroke Neurology

Author

Kernan, Walter N., Forman, Rachel, and Inzucchi, Silvio E.

Abstract

Diabetes is a heterogeneous disease that affects 9% of the world’s population (11% in the United States). The consequences of diabetes for the brain are severe; it nearly doubles a person’s risk of stroke and is a major contributor to risk for cerebral small vessel disease and dementia. These effects on the brain are in addition to peripheral neuropathy, retinopathy, nephropathy, and coronary heart disease. In this article, we explain the treatments that can prevent or mitigate its harmful effects and propose a role for neurologists and other neurology clinicians in managing patients during routine care.

Published
2023
Full Text
View/download PDF

299. IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction

Author

Adamson, Carly, Welsh, Paul, Docherty, Kieran F., de Boer, Rudolf A., Diez, Mirta, Drożdż, Jarosław, Dukát, Andre, Inzucchi, Silvio E., Køber, Lars, Kosiborod, Mikhail N., Ljungman, Charlotta E.A., Martinez, Felipe A., Ponikowski, Piotr, Sabatine, Marc S., Morrow, David A., Lindholm, Daniel, Hammarstedt, Ann, Boulton, David W., Greasley, Peter J., Langkilde, Anna Maria, Solomon, Scott D., Sattar, Naveed, McMurray, John J.V., and Jhund, Pardeep S.

Abstract

Insulin-like growth factor–binding protein-7 (IGFBP-7) has been proposed as a potential prognostic biomarker in heart failure (HF), but the association between elevation in IGFBP-7 and HF outcomes in ambulant patients with heart failure with reduced ejection fraction (HFrEF) is unknown.

Published
2023
Full Text
View/download PDF

300. Sex Differences in Characteristics, Outcomes, and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure: Insights From DAPA-HF and DELIVER

Author

Wang, Xiaowen, Vaduganathan, Muthiah, Claggett, Brian L., Hegde, Sheila M., Pabon, Maria, Kulac, Ian J., Vardeny, Orly, O’Meara, Eileen, Zieroth, Shelley, Katova, Tzvetana, McGrath, Martina M., Pouleur, Anne-Catherine, Jhund, Pardeep S., Desai, Akshay S., Inzucchi, Silvio E., Kosiborod, Mikhail N., de Boer, Rudolf A., Kober, Lars, Sabatine, Marc S., Martinez, Felipe A., Ponikowski, Piotr, Shah, Sanjiv J., Hernandez, Adrian F., Langkilde, Anna Maria, McMurray, John J.V., Solomon, Scott D., and Lam, Carolyn S.P.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results